IP Library Granted Patent US 10,927,147
Granted Patent B2
US 10,927,147 · App. 16/060,093 · Granted Feb 23, 2021

Muramyl peptide derivative compound, synthesis and uses thereof

Inventors: Krishna Murthy Ella (Hyderabad, IN); Ganneru Brunda (Hyderabad, IN); Halmathur Mahabalarao Sampath Kumar (Hyderabad, IN); Miryala Sreekanth (Hyderabad, IN)
Assignees: Bharat Biotech International Limited; Council of Scientific and Industrial Research
C07K9/005A61K39/12A61K38/00A61K2039/5555A61K2039/572A61K2039/575A61P31/04A61P31/12A61P33/00C12N2710/00034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,147
App. No.
16/060,093
Granted
Feb 23, 2021
Kind
B2
Abstract

The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.

Claims (7)

1. A compound comprising a muramyl dipeptide of the formula:

2. The compound of claim 1 , which comprises an IR profile characterized by IR (n in cm′ 1 ): 3273, 2936, 1653, 1552, 1417, 1253, 1026.

3. The compound of claim 1 , which comprises an NMR profile characterized by 1H-NMR (300 MHz, DMSO-d 6 ): δ 4.66 (d, =6.421, 1H), 4.25 (m, 1H), 3.96 (m, 3H), 3.37 (q, =6.987, 3H), 3.19-3.16 (m, 2H), 2.17 (m, 2H), 1.99 (m, 1H), 1.24 (m, 4H), 1.15 (d, =6.409, 3H), 1.08 (t, =6.987, 3H).

4. A vaccine formulation comprising the compound of claim 1 .

5. The vaccine formulation of claim 4 , further comprising an antigen selected from the group consisting of a live attenuated vaccine antigen, inactivated vaccine antigen, subunit vaccine antigen, a conjugate vaccine antigen, a recombinant vaccine antigen, and combinations thereof.

6. The vaccine formulation of claim 5 , further comprising a vaccine component against an infectious pathogen.

7. The vaccine formulation of claim 6 , wherein the infectious pathogen comprises bacteria, virus, or a mammalian pathogen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2018
From: ELLA, KRISHNA MURTHY; BRUNDA, GANNERU; KUMAR, HALMATHUR MAHABALARAL SAMPATH; SREEKANTH, MIRYALA
To: BHARAT BIOTECH INTERNATIONAL LTD.; COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Reel/Frame 046884/0892 →
Priority Claims (1)
IN 6436/CHE/2015 · Dec 10, 2015 · national
Continuity (1)
Related Publication 20180371023A1 · Dec 27, 2018